Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gross Profit (2016)

Historic Gross Profit for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Q4 2016 value amounting to -$183000.0.

  • Viridian Therapeutics, Inc.\DE's Gross Profit fell 25775.86% to -$183000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $929000.0, marking a year-over-year decrease of 1970.61%. This contributed to the annual value of $929000.0 for FY2016, which is 452380.95% up from last year.
  • As of Q4 2016, Viridian Therapeutics, Inc.\DE's Gross Profit stood at -$183000.0, which was down 25775.86% from $337000.0 recorded in Q3 2016.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Gross Profit registered a high of $972000.0 during Q3 2014, and its lowest value of -$295000.0 during Q3 2015.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Gross Profit averaged around $433666.7, with its median value being $522000.0 (2015).
  • Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's Gross Profit was 21423.73% (2016), while the steepest drop was 25775.86% (2016).
  • Viridian Therapeutics, Inc.\DE's Gross Profit (Quarter) stood at $726000.0 in 2014, then tumbled by 84.02% to $116000.0 in 2015, then plummeted by 257.76% to -$183000.0 in 2016.
  • Its Gross Profit stands at -$183000.0 for Q4 2016, versus $337000.0 for Q3 2016 and $487000.0 for Q2 2016.